Novartis ended 2021 on a good note, with key drugs (like Cosentyx and Entresto) offsetting weakness and/or restrained growth in other areas. While the 2022 profitability guidance came in lower than our expectations, it was due to sustained troubles in Sandoz – which is already under strategic review. Fortunately, Sandoz is garnering significant interest from various buyers. Overall, with core pharma virtues intact and Sandoz being side-lined gradually, Novartis remains an attractive sector bet. ....
03 Feb 2022
A good Q4 sums up 2021 recovery; but all eyes on Sandoz
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A good Q4 sums up 2021 recovery; but all eyes on Sandoz
Novartis ended 2021 on a good note, with key drugs (like Cosentyx and Entresto) offsetting weakness and/or restrained growth in other areas. While the 2022 profitability guidance came in lower than our expectations, it was due to sustained troubles in Sandoz – which is already under strategic review. Fortunately, Sandoz is garnering significant interest from various buyers. Overall, with core pharma virtues intact and Sandoz being side-lined gradually, Novartis remains an attractive sector bet. ....